Name: Latest research reports of Suven Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Suven Pharmaceuticals Ltd.
Rating: 5
Author: ICICI Securities Limited

Suven Pharmaceuticals Ltd.

NSE: SUVENPHAR | BSE: 543064 | ISIN: INE03QK01018 | Industry: Pharmaceuticals
| Expensive Performer

1074.0500 -76.95 (-6.69%)

NSE Apr 01, 2025 15:31 PM

79.61% Gain from 52W Low

Volume: 552.9K

Suven Pharmaceuticals Ltd.

11 Feb 2021

1074.05

-6.69%

Suven Pharmaceuticals

Buy: Suven Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Overall 15-20% revenue growth guidance for FY21 continued, hope to achieve same in FY22; EBITDA margins sustainable above 40% o Pharma CRAMS to also grow 15-20% YoY; specialty chemical...

Suven Pharmaceuticals Ltd. has gained 58.63% in the last 1 Year